Personalis & BC Cancer Assess Benefits of ctDNA for Colorectal, Pancreatic Cancers
Personalis and BC Cancer will deploy a personalized liquid biopsy-based assay for a study of patients with colorectal and pancreatic cancers.
Category: Pancreatic
Pancreatic
Latest
Pancreatic
Latest
‘Electronic Nose’ Accurately Sniffs Out Hard-to-Detect Cancers
An odor-based test that sniffs out vapors emanating from blood samples was able to distinguish cancer cells with up to 95% accuracy.
Pancreatic
Latest
Study Offers Promise for Multicancer Detection from a Single Blood Draw
Bluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.
Biomarker Test Accurately Detects Early-Stage Pancreatic Cancer
Immunovia’s serum biomarker microarray detects pancreatic cancer in the early stages of development with 96% accuracy.
Read More
Linköping University Hospital Joins Clinical Study for Early Detection of Pancreatic Cancer
The PanFAM-1 study is designed to validate Immunovia’s IMMray PanCan-d assay, the first blood-based test for early detection of pancreatic cancer.
Read More
Spanish Hospital Joins World’s Largest Study of Risk for Familial Pancreatic Cancer
Designed to validate Immunovia’s blood-based test for familial pancreatic cancer risk, the study will analyze more than 1,000 individuals across sites in the United States and Europe.
Read More
Ortho Clinical Diagnostics Launches C-Peptide Assay
Ortho Clinical Diagnostics has launched the Vitros Immunodiagnostic Products C-Peptide reagent pack and calibrators, which broadens the company’s menu of tests for all aspects of diabetes and other pancreatic disorders.
Read MoreThermo Fisher Scientific Expands Its Liquid Biopsy and Immunooncology Portfolio
Thermo Fisher Scientific has expanded its Oncomine portfolio with new assays for liquid biopsy and immunooncology.
Read More
Delivering on the Promise of NGS for Clinical Diagnostics
Presenting an evaluation of the GeneReader next-generation sequencing (NGS) system, the article assesses the performance of the system in comparison with an alternative NGS technology.
Read More
January/February 2018 Product Spotlight: Laboratory Reagents and Consumables
This month’s issue features laboratory reagents and consumables from such companies as Audit Microcontrols, Bio-rad Laboratories, and Diasorin Molecular.
Read MoreStudy Supports Use of DiviTum for Evaluation of Pancreatic Cancer
The proof-of-concept study, done in collaboration with researchers at the University of Heidelberg, provides evidence for using DiviTum as a dynamic biomarker before and during therapy to give important answers regarding prognosis and therapy efficacy.
Read More
Roche Releases Tissue Dissection Instrument
The instrument utilizes an automated digitally assisted process to isolate clinically relevant cells from formalin-fixed paraffin-embedded tissue slides.
Read MoreInside Track: A Fresh Look at Colorectal Cancer
David A. Ahlquist, MD, coinventor of the Cologuard stool-based DNA screening test for colorectal cancer, discusses updated USPSTF guidelines that seek to increase screening rates.
Read More
October 2015: Product News
This month’s Product News features an LED illuminator from Excelitas Technologies, a pancreatic cancer test from Interpace Diagnostics, and an integrated hardware and software system from Carl Zeiss Microscopy.
Read More
Test Integrates Analysis of DNA and Clinical Features of Pancreatic Cysts
Assessing multiple tumor suppressor and oncogene DNA abnormalities, the test combines analysis of DNA and clinical features of pancreatic cysts to stratify patients for risk of pancreatic adenocarcinoma.
Read More
March 2015 Product Spotlight: Cancer Diagnostics
Featured cancer diagnostics products include the Therascreen EGFR RGQ Plasma PCR kit from Qiagen, a KRAS screening multiplex kit from Bio-Rad Laboratories, and the Prostate Health Index from Beckman Coulter Diagnostics.
Read More
Moffitt Cancer Center Study Discovers Biological Markers Associated with High-Risk Pancreatic Lesions
In a recent study, Moffitt researchers find that microRNAs may enable clinicians to distinguish between high-risk and low-risk pancreatic lesions.
Read More
Invitae Announces Favorable Reimbursement Coverage Decisions
With reimbursement coverage from Blue Shield of California and acceptance as a Medicare provider, Invitae looks to bring genetic testing into mainstream medicine.
Read More